Bambusa Therapeutics Initiated BBT001 Subcutaneous Dosing
The Phase 1 trial for atopic dermatitis tests whether a bispecific antibody can enable quarterly maintenance dosing.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe medical research prioritizes convenient treatment administration for patients with chronic inflammatory skin diseases?
Bambusa Therapeutics has administered the first subcutaneous dose of its drug candidate BBT001 to a patient in New Zealand. The Phase 1 clinical trial is currently enrolling up to 45 patients across the United States, Australia, Europe, and New Zealand to test safety and pharmacokinetics.
Why it matters
The study aims to determine if the 33-day half-life of this bispecific antibody—a laboratory-engineered protein that binds to two distinct targets—is sufficient to support maintenance dosing once every three months. This development targets atopic dermatitis, a condition currently requiring more frequent intervention.
BBT001 is a bispecific antibody targeting IL-4Rα and IL-31 with an approximate 33-day half-life. Participants in the study receive five doses of either 360 mg or 720 mg over a 12-week evaluation period.
The players
Bambusa Therapeutics
A biotechnology company based in Boston developing bispecific antibodies for inflammatory conditions.
The details
The drug candidate utilizes a bispecific architecture, which functions by binding to two different protein targets simultaneously to interrupt inflammatory signaling pathways. The current Phase 1 trial evaluates the safety and tolerability of this delivery method following successful preliminary proof-of-concept results from intravenous trials reported in July 2026. Researchers are measuring clinical activity, including EASI (Eczema Area and Severity Index) improvements, throughout the 12-week dosing schedule.
Timeline
July 2026: Bambusa reported preliminary intravenous proof-of-concept results.
October 1, 2026: The first subcutaneous patient dose was administered.
The Tech Race
This effort follows the established industry trend of targeting dual cytokine pathways to improve outcomes in dermatological conditions. It marks a departure from existing therapies by attempting to leverage an extended 33-day half-life to enable quarterly maintenance dosing.
The current trial evaluates whether patients with moderate-to-severe atopic dermatitis can eventually transition to a maintenance schedule of once every three months. Availability and pricing remain unannounced as the drug is still in the early stages of clinical testing.
The takeaway
The success of this trial hinges on whether the subcutaneous delivery maintains the clinical activity observed in earlier intravenous studies. Future updates will focus on the results of the 12-week evaluation and the subsequent design of the planned Phase 2b study.
Further reading
For more on the current pipeline of antibody therapies, visit Biotech.
More information
View official updates on the trial and company research on the Bambusa Therapeutics corporate website.
Live Poll
Do you believe medical research prioritizes convenient treatment administration for patients with chronic inflammatory skin diseases?
